No Detail Found!

Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors.

Author(s)
Dalal M. Nemanqani Department of Pathology, King Abdul Aziz Specialist Hospital, Taif, Kingdom of Saudi Arabia
Kanwal Aftab Department of Pathology, King Abdul Aziz Specialist Hospital, Taif, Kingdom of Saudi Arabia
Samia H. Al Malki Medical Student, College of Medicine, Taif University, Taif, Kingdom of, Saudi Arabia
Walaa M. Al Sufyani Medical Student, College of Medicine, Taif University, Taif, Kingdom of, Saudi Arabia
Abstract
Objective: To identify the expression of epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) and its relationship with clinicopathologic factors. Study Design: Descriptive study. Place and Duration of Study: Department of Laboratory and Blood Bank, King Abdul Aziz Specialist Hospital, Taif, Saudia Arabia, from January 2008 to June 2011. Methodology: Diagnosed cases of colorectal carcinoma reports and slides were reviewed and cilnicopathological features were recorded. EGFR immunohistochemical staining was performed. All slides were assessed by light microscopy and scored after assessing the percentage of cells staining (grade) and intensity of the staining. Colectomy specimens of colorectal carcinomas with complete clinical information and good fixation were included. Biopsies specimens diagnosed as colorectal adenocarcinomas were excluded. The studied characteristics included age, gender, clinical presentation, tumor site, tumor size, degree of histological differentiation (well, moderate, poor), vascular and perineural invasion. Statistical analysis was done by SPSS version14 and Chi-square test was used for comparing the histological factors with EGFR expression. Results: Thirty-five colectomy specimens showed mean age of 61.5 ±12.36 years and male to female ratio 1:2 (35% and 65%, respectively). Expression of EGFR was detected in 74% of the studied specimens. There was strong expression in most of cases. EGFR expression was found in mostly grade II (85%) and stage T3 tumors (69%). Conclusion: Patients presented mostly with late stages of CRC and EGFR was expressed on tumor cells in the majority.
Publication Details
Page(s) 527-531
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 7, Year: 2018

Request the full text from PASTIC

References
FerlayJ,BrayF,PisaniP,ParkinDM. GLOBOCAN, 2004.Cancer incidence, mortality, and prevalence worldwide,IACR Cancer Base, No.5, Version 2 -
EzzeldinM,AhmedA,TawfikR,AboelkhairM,Bakr M. Past, 2008.present and future of colorectal cancer in Kingdom of Saudi Arabia,Saudi J Gastroentrol 14 178 -82
CarolyC,PeterF,LawrenceJ,HarryS,StanleyR, 2000.Prognostic factors in colorectal cancer, College of American Pathologist Consensus Statement 1999,Arch Pathol Lab Med 124 -
MayerA,TakimotoM., 1993.The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer,Cancer 71 2454 -60
SpanoJ,FagradR,SoriaJ,RixeO,KhayatD., 2005.Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives,Ann Oncol 16 189 -94
DebucquoyI,MachielsJ,McBrideW,HaustermansK., 2010.Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation,Clin Cancer Res 15 2709 -14
DeschoolmeesterV,BayM,SpecenierP,LardonF,VermorkenJB, 2010.A Review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy,Oncologist 15 699 -731
SteeleRJ,KellyP,EllulB, 1990.Immunohistochemical detection of epidermal growth factor receptors on human colonic carcinomas,Br J Cancer 61 325 -6
SaltzLB,MeropolNJ,LoehrerPJ, 2004.Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor,J Clin Oncol 22 1201 -8
Al-AhwalMS,AL-GhamdiAA, 2005.Pattern of colorectal cancer at two hospitals in the western region of Saudi Arabia,Saudi J Gastroenterol 11 164 -9
StephenB,CarolynC, 2010.The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM,Ann Surg Oncol 17 1471 -4
GoldsteinNS,ArminM., 2001.Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma,Cancer 92 1331 -46
SpanoJP,LagorceC,AtlanD,MilanoG,DomontJ, 2005.Impact of EGFR expression on colorectal cancer patient prognosis and survival,Ann Oncol 16 102 -8
2004.National cancer registry, ministry of health,Kingdom of Saudi Arabia 1999 -2000
LaohavinijS,ManeechavakajornJ,TechatanolP, 2010.Prognostic factors for survival in colorectal cancer patients,J Med Assoc Thai 93 1156 -66
PatelDK., 2008.Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer,Pharmacotherapy 28 31S -41S
LockhartAC, 2005.The epidermal growth factor receptor as a target for colorectal cancer therapy,Semin Oncol 32 52 -60
LetoSM,TrusolinoL, 2014.Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies,J Mol Med 92 709 -22
OkadaY,MiyamotoH,GojiT,TakayamaT, 2014.Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer,Digestion 89 18 -23
LyallMS,DundasSR,CurranS,MurrayGI, 2006.Profilling markers of prognosis in colorectal cancer,Clin Cancer Res 12 1184 -91
GaliziaG,LietoE,FeraraccioF,DeitaF, 2006.Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery,Ann Surg Oncol 13 823 -35
0

Citations

0

Downloads

146

Views